Steven Robinette is a principal and focuses on the formation and operations of companies translating emerging biology into novel therapeutics. Steven was a member of the founding teams of Kymera Therapeutics and Disarm Therapeutics, and serves as a board observer for a number of portfolio companies including Lysosomal Therapeutics, Cadent Therapeutics, and Spero Therapeutics. Prior to joining Atlas Venture in 2015, Steven was an engagement manager at McKinsey & Company, serving pharmaceutical and biotechnology clients on R&D topics including investment strategy, asset diligence, and pipeline prioritization.
Steven received his Ph.D. from Imperial College London, where he studied the biochemical genetics of rare disease in the laboratory of Jeremy Nicholson, and through a graduate partnership program with the laboratory of William Gahl at the National Human Genome Research Institute. Steven’s graduate work was sponsored by the British Marshall Scholarship, the NSF Graduate Research Fellowship Program, and the NIH Oxford-Cambridge Scholars Program. Steven received his B.S. in biochemistry and molecular biology from the University of Florida where he graduated summa cum laude, valedictorian and was a Barry Goldwater Scholar.
Outside of the office, Steven spends as much time as he can outdoors; hiking, skiing, and in the garden and orchard. He and his wife live in Fremont, NH.